Duchenne Muscular Dystrophy Drugs Market by Type and Application - Global Industry Analysis & Forecast to 2027

Published On : May 2020 Pages : 180 Category: Pharma & Healthcare Report Code : HC0511034

Duchenne Muscular Dystrophy Drugs Market by Type (Molecular-based Therapies, Steroid Therapy) Application (Hospitals/Clinics, Ambulatory Centers, Other End Users) - Global Industry Analysis & Forecast to 2027

Industry Outlook and Trend Analysis

The Duchenne Muscular Dystrophy Drugs Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Duchenne Muscular Dystrophy Drugs is genetic rare muscle disorders affecting about 1 in 3,500 male births worldwide. Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass. In muscular dystrophy, abnormal genes (mutations) interfere with the production of proteins needed to form healthy muscle.

Drivers and Restraints

Top-down and bottom-up approaches are used to validate the global market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.

Regional Insights

The data for 2019 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Columbia
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of MEA

Competitive Analysis         

The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

    • BioMarin
    • Bristol-Myers Squibb Company
    • Fibrogen Inc.
    • Eli Lilly and Company
    • Nobelpharma Co. Ltd
    • NS Pharma Inc.
    • Pfizer Inc.
    • PTC Therapeutics
    • Santhera Pharmaceuticals
    • Sarepta Therapeutics

Some of the key questions answered by the report are:

  • What was the market size in 2016 and forecast from 2020 to 2027?
  • What will be the industry market growth from 2016 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

·         Duchenne Muscular Dystrophy Drugs Market, By Type, Estimates and Forecast, 2016-2027 ($Million)

o    Molecular-based Therapies

o    Steroid Therapy

·         Duchenne Muscular Dystrophy Drugs Market, By Application, Estimates and Forecast, 2016-2027 ($Million)

o    Hospitals/Clinics

o    Ambulatory Centers

o    Other End Users

·         Duchenne Muscular Dystrophy Drugs Market, By Key Players, Estimates and Forecast, 2016-2027 ($Million)

o    BioMarin

o    Bristol-Myers Squibb Company

o    Fibrogen Inc.

o    Eli Lilly and Company

o    Nobelpharma Co. Ltd

o    NS Pharma Inc.

o    Pfizer Inc.

o    PTC Therapeutics

o    Santhera Pharmaceuticals

o    Sarepta Therapeutics

·         Duchenne Muscular Dystrophy Drugs Market, By Region, Estimates and Forecast, 2016-2027 ($Million)

o    North America

§  North America Submarine Cables Market, By Country

o    U.S. Submarine Cables Market

o    Canada Submarine Cables Market

o    Mexico Submarine Cables Market

o    Europe

§  Europe Submarine Cables Market, By Country

o    Germany Submarine Cables Market

o    UK Submarine Cables Market

o    France Submarine Cables Market

o    Russia Submarine Cables Market

o    Italy Submarine Cables Market

o    Rest of Europe Submarine Cables Market

o    Asia-Pacific

§  Asia-Pacific Submarine Cables Market, By Country

o    China Submarine Cables Market

o    Japan Submarine Cables Market

o    South Korea Submarine Cables Market

o    India Submarine Cables Market

o    Southeast Asia Submarine Cables Market

o    Rest of Asia-Pacific Submarine Cables Market

o    South America

§  South America Submarine Cables Market

o    Brazil Submarine Cables Market

o    Argentina Submarine Cables Market

o    Columbia Submarine Cables Market

o    Rest of South America Submarine Cables Market

o    Middle East and Africa

§  Middle East and Africa Submarine Cables Market

o    Saudi Arabia Submarine Cables Market

o    UAE Submarine Cables Market

o    Egypt Submarine Cables Market

o    Nigeria Submarine Cables Market

o    South Africa Submarine Cables Market

o    Rest of MEA Submarine Cables Market

Table of Contents:

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2016-2027)

4.1.2.  Canada Market Status and Outlook (2016-2027)

4.1.3.  Mexico Market Status and Outlook (2016-2027)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2016-2027)

4.2.2.  France Market Status and Outlook (2016-2027)

4.2.3.  UK Market Status and Outlook (2016-2027)

4.2.4.  Russia Market Status and Outlook (2016-2027)

4.2.5.  Italy Market Status and Outlook (2016-2027)

4.2.6.  Rest of Europe Market Status and Outlook (2016-2027)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2016-2027)

4.3.2.  Japan Market Status and Outlook (2016-2027)

4.3.3.  Korea Market Status and Outlook (2016-2027)

4.3.4.  India Market Status and Outlook (2016-2027)

4.3.5.  Southeast Asia Market Status and Outlook (2016-2027)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2016-2027)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2016-2027)

4.4.2.  Argentina Market Status and Outlook (2016-2027)

4.4.3.  Columbia Market Status and Outlook (2016-2027)

4.4.4.  Rest of South America Market Status and Outlook (2016-2027)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2016-2027)

4.5.2.  United Arab Emirates Market Status and Outlook (2016-2027)

4.5.3.  Egypt Market Status and Outlook (2016-2027)

4.5.4.  Nigeria Market Status and Outlook (2016-2027)

4.5.5.  South Africa Market Status and Outlook (2016-2027)

4.5.6.  Turkey Market Status and Outlook (2016-2027)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2016-2027)

5.       Duchenne Muscular Dystrophy Drugs  Market, By Type

5.1.     Introduction

5.2.     Global Duchenne Muscular Dystrophy Drugs  Revenue and Market Share by Type (2016-2019)

5.2.1.  Global Duchenne Muscular Dystrophy Drugs  Revenue and Revenue Share by Type (2016-2019)

5.3.     Molecular-based Therapies

5.3.1.  Global Molecular-based Therapies Revenue and Growth Rate (2016-2019)

5.4.     Steroid Therapy

5.4.1.  Global Steroid Therapy Revenue and Growth Rate (2016-2019)

6.       Duchenne Muscular Dystrophy Drugs  Market, By Applications

6.1.     Introduction

6.2.     Global Duchenne Muscular Dystrophy Drugs  Revenue and Market Share by Applications (2016-2019)

6.2.1.  Global Duchenne Muscular Dystrophy Drugs  Revenue and Revenue Share by Applications (2016-2019)

6.3.     Hospitals/Clinics

6.3.1.  Global Hospitals/Clinics Revenue and Growth Rate (2016-2019)

6.4.     Ambulatory Centers

6.4.1.  Global Ambulatory Centers Revenue and Growth Rate (2016-2019)

6.5.     Other

6.5.1.  Global Other  Revenue and Growth Rate (2016-2019)

7.       Duchenne Muscular Dystrophy Drugs  Market, By Region

7.1.     Introduction

7.2.     Global Duchenne Muscular Dystrophy Drugs  Revenue and Market Share by Regions

7.2.1.  Global Duchenne Muscular Dystrophy Drugs  Revenue by Regions (2016-2019)

7.3.     North America Duchenne Muscular Dystrophy Drugs  by Countries

7.3.1.  North America Duchenne Muscular Dystrophy Drugs  Revenue and Growth Rate (2016-2019)

7.3.2.  North America Duchenne Muscular Dystrophy Drugs  Revenue (Million USD) by Countries (2016-2019)

7.3.3.  United States

7.3.3.1.  United States Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.3.4.  Canada

7.3.4.1.  Canada Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.3.5.  Mexico

7.3.5.1.  Mexico Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.4.     Europe Duchenne Muscular Dystrophy Drugs  by Countries

7.4.1.  Europe Duchenne Muscular Dystrophy Drugs  Revenue and Growth Rate (2016-2019)

7.4.2.  Europe Duchenne Muscular Dystrophy Drugs  Revenue (Million USD) by Countries (2016-2019)

7.4.3.  Germany

7.4.3.1.  Germany Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.4.4.  France

7.4.4.1.  France Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.4.5.  UK

7.4.5.1.  UK Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.4.6.  Russia

7.4.6.1.  Russia Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.4.7.  Italy

7.4.7.1.  Italy Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.4.8.  Rest of Europe

7.4.8.1.  Rest of Europe Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.5.     Asia-Pacific Duchenne Muscular Dystrophy Drugs  by Countries

7.5.1.  Asia-Pacific Duchenne Muscular Dystrophy Drugs  Revenue and Growth Rate (2016-2019)

7.5.2.  Asia-Pacific Duchenne Muscular Dystrophy Drugs  Revenue (Million USD) by Countries (2016-2019)

7.5.3.  China

7.5.3.1.  China Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.5.4.  Japan

7.5.4.1.  Japan Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.5.5.  Korea

7.5.5.1.  Korea Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.5.6.  India

7.5.6.1.  India Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.5.7.  Southeast Asia

7.5.7.1.  Southeast Asia Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.5.8.  Rest of Asia-Pacific

7.5.8.1.  Rest of Asia-Pacific Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.6.     South America Duchenne Muscular Dystrophy Drugs  by Countries

7.6.1.  South America Duchenne Muscular Dystrophy Drugs  Revenue and Growth Rate (2016-2019)

7.6.2.  South America Duchenne Muscular Dystrophy Drugs  Revenue (Million USD) by Countries (2016-2019)

7.6.3.  Brazil

7.6.3.1.  Brazil Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.6.4.  Argentina

7.6.4.1.  Argentina Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.6.5.  Columbia

7.6.5.1.  Columbia Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.6.6.  Rest of South America

7.6.6.1.  Rest of South America Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.7.     Middle East and Africa Duchenne Muscular Dystrophy Drugs  by Countries

7.7.1.  Middle East and Africa Duchenne Muscular Dystrophy Drugs  Revenue and Growth Rate (2016-2019)

7.7.2.  Middle East and Africa Duchenne Muscular Dystrophy Drugs  Revenue (Million USD) by Countries (2016-2019)

7.7.3.  Saudi Arabia

7.7.3.1.  Saudi Arabia Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.7.4.  United Arab Emirates

7.7.4.1.  United Arab Emirates Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.7.5.  Egypt

7.7.5.1.  Egypt Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.7.6.  Nigeria

7.7.6.1.  Nigeria Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.7.7.  South Africa

7.7.7.1.  South Africa Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.7.8.  Turkey

7.7.8.1.  Turkey Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

7.7.9.  Rest of Middle East and Africa

7.7.9.1.  Rest of Middle East and Africa Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2016-2019)

8.       Company Profiles

8.1.     BioMarin

8.1.1.  Business Overview

8.1.2.   Service Portfolio

8.1.3.  Strategic Developments

8.1.4.  Financial Overview

8.2.     Bristol-Myers Squibb Company

8.2.1.  Business Overview

8.2.2.   Service Portfolio

8.2.3.  Strategic Developments

8.2.4.  Financial Overview

8.3.     Fibrogen Inc.

8.3.1.  Business Overview

8.3.2.   Service Portfolio

8.3.3.  Strategic Developments

8.3.4.  Financial Overview

8.4.     Eli Lilly and Company

8.4.1.  Business Overview

8.4.2.   Service Portfolio

8.4.3.  Strategic Developments

8.4.4.  Financial Overview

8.5.     Nobelpharma Co. Ltd

8.5.1.  Business Overview

8.5.2.   Service Portfolio

8.5.3.  Strategic Developments

8.5.4.  Financial Overview

8.6.     NS Pharma Inc.

8.6.1.  Business Overview

8.6.2.   Service Portfolio

8.6.3.  Strategic Developments

8.6.4.  Financial Overview

8.7.     Pfizer Inc.

8.7.1.  Business Overview

8.7.2.   Service Portfolio

8.7.3.  Strategic Developments

8.7.4.  Financial Overview

8.8.     PTC Therapeutics

8.8.1.  Business Overview

8.8.2.   Service Portfolio

8.8.3.  Strategic Developments

8.8.4.  Financial Overview

8.9.     Santhera Pharmaceuticals

8.9.1.  Business Overview

8.9.2.   Service Portfolio

8.9.3.  Strategic Developments

8.9.4.  Financial Overview

8.10. Sarepta Therapeutics

8.10.1.      Business Overview

8.10.2.       Service Portfolio

8.10.3.      Strategic Developments

8.10.4.      Financial Overview

9.       Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.1.     Global Duchenne Muscular Dystrophy Drugs  Revenue (Millions USD) and Growth Rate (2019-2027)

9.2.     Duchenne Muscular Dystrophy Drugs  Market Forecast by Regions (2019-2027)

9.2.1.  North America Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.1.1.  United States Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.1.2.  Canada Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.1.3.  Mexico Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.2.  Europe Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.2.1.  Germany Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.2.2.  France Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.2.3.  UK Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.2.4.  Russia Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.2.5.  Italy Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.2.6.  Rest of Europe Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.3.  Asia-Pacific Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.3.1.  China Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.3.2.  Japan Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.3.3.  Korea Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.3.4.  India Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.3.5.  Southeast Asia Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.3.6.  Rest of Asia-Pacific Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.4.  South America Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.4.1.  Brazil Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.4.2.  Argentina Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.4.3.  Columbia Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.4.4.  Rest of South America Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.5.  Middle East and Africa Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.5.1.  Saudi Arabia Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.5.2.  United Arab Emirates Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.5.3.  Egypt Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.5.4.  Nigeria Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.5.5.  South Africa Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.5.6.  Turkey Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.2.5.7.  Rest of Middle East and Africa Duchenne Muscular Dystrophy Drugs  Market Forecast (2019-2027)

9.3.     Duchenne Muscular Dystrophy Drugs  Market Forecast by Type (2019-2027)

9.3.1.  Duchenne Muscular Dystrophy Drugs  Forecast by Type (2019-2027)

9.3.2.  Duchenne Muscular Dystrophy Drugs  Market Share Forecast by Type (2019-2027)

9.4.     Duchenne Muscular Dystrophy Drugs  Market Forecast by Applications (2019-2027)

9.4.1.  Duchenne Muscular Dystrophy Drugs  Forecast by Applications (2019-2027)

9.4.2.  Duchenne Muscular Dystrophy Drugs  Market Share Forecast by Applications (2019-2027)


List of Tables

List of Tables and Figures:

Figure United States Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Canada Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Mexico Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Germany Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure France Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure UK Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Russia Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Italy Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Rest of Europe Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure China Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Japan Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Korea Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure India Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Southeast Asia Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Rest of Asia-Pacific Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Brazil Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Argentina Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Columbia Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Rest of South America Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Saudi Arabia Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure United Arab Emirates Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Egypt Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Nigeria Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure South Africa Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Turkey Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Figure Rest of Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue (Million USD) and Growth Rate (2016-2027)
Table Global Duchenne Muscular Dystrophy Drugs Revenue and Revenue Share by Type (2016-2019)
Figure Global Molecular-based Therapies Revenue and Growth Rate (2016-2019)
Figure Global Steroid Therapy Revenue and Growth Rate (2016-2019)
Table Global Duchenne Muscular Dystrophy Drugs Revenue and Revenue Share by Applications (2016-2019)
Figure Global Hospitals/Clinics Revenue and Growth Rate (2016-2019)
Figure Global Ambulatory Centers Revenue and Growth Rate (2016-2019)
Figure Global Other Revenue and Growth Rate (2016-2019)
Table Global Duchenne Muscular Dystrophy Drugs Revenue by Regions (2016-2019)
Figure North America Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure North America Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate (2016-2019)
Figure North America Duchenne Muscular Dystrophy Drugs by Countries (2016-2019)
Figure North America Duchenne Muscular Dystrophy Drugs Revenue (Million USD) by Countries (2016-2019)
Figure United States Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure United States Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Canada Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Canada Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Mexico Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Mexico Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Europe Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Europe Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate (2016-2019)
Figure Europe Duchenne Muscular Dystrophy Drugs by Countries (2016-2019)
Figure Europe Duchenne Muscular Dystrophy Drugs Revenue (Million USD) by Countries (2016-2019)
Figure Germany Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Germany Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure France Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure France Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure UK Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure UK Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Russia Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Russia Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Italy Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Italy Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Rest of Europe Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Rest of Europe Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Asia-Pacific Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Asia-Pacific Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate (2016-2019)
Figure Asia-Pacific Duchenne Muscular Dystrophy Drugs by Countries (2016-2019)
Figure Asia-Pacific Duchenne Muscular Dystrophy Drugs Revenue (Million USD) by Countries (2016-2019)
Figure China Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure China Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Japan Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Japan Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Korea Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Korea Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure India Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure India Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Southeast Asia Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Southeast Asia Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Rest of Asia-Pacific Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Rest of Asia-Pacific Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure South America Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure South America Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate (2016-2019)
Figure South America Duchenne Muscular Dystrophy Drugs by Countries (2016-2019)
Figure South America Duchenne Muscular Dystrophy Drugs Revenue (Million USD) by Countries (2016-2019)
Figure Brazil Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Brazil Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Argentina Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Argentina Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Columbia Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Columbia Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Rest of South America Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Rest of South America Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Middle East and Africa Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate (2016-2019)
Figure Middle East and Africa Duchenne Muscular Dystrophy Drugs by Countries (2016-2019)
Figure Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue (Million USD) by Countries (2016-2019)
Figure Saudi Arabia Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Saudi Arabia Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure United Arab Emirates Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure United Arab Emirates Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Egypt Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Egypt Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Nigeria Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Nigeria Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure South Africa Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure South Africa Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Turkey Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Turkey Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Figure Rest of Middle East and Africa Duchenne Muscular Dystrophy Drugs Growth Rate (2016-2019)
Figure Rest of Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2016-2019)
Table BioMarin Duchenne Muscular Dystrophy Drugs Financial Overview
Table Bristol-Myers Squibb Company Duchenne Muscular Dystrophy Drugs Financial Overview
Table Fibrogen Inc. Duchenne Muscular Dystrophy Drugs Financial Overview
Table Eli Lilly and Company Duchenne Muscular Dystrophy Drugs Financial Overview
Table Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Financial Overview
Table NS Pharma Inc. Duchenne Muscular Dystrophy Drugs Financial Overview
Table Pfizer Inc. Duchenne Muscular Dystrophy Drugs Financial Overview
Table PTC Therapeutics Duchenne Muscular Dystrophy Drugs Financial Overview
Table Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Financial Overview
Table Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Financial Overview
Figure Global Duchenne Muscular Dystrophy Drugs Revenue (Millions USD) and Growth Rate (2019-2027)
Table Duchenne Muscular Dystrophy Drugs Market Forecast by Regions (2019-2027)
Figure North America Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure United States Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Canada Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Mexico Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Europe Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Germany Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure France Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure UK Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Russia Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Italy Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Rest of Europe Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure China Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Japan Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Korea Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure India Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Southeast Asia Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure South America Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Brazil Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Argentina Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Columbia Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Rest of South America Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Saudi Arabia Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure United Arab Emirates Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Egypt Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Nigeria Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure South Africa Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Turkey Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Forecast (2019-2027)
Figure Global Duchenne Muscular Dystrophy Drugs Forecast by Type (2019-2027)
Figure Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Type (2019-2027)
Figure Global Duchenne Muscular Dystrophy Drugs Forecast by Type (2019-2027)
Figure Global Duchenne Muscular Dystrophy Drugs Forecast by Applications (2019-2027)
Figure Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Applications (2019-2027)
Figure Global Duchenne Muscular Dystrophy Drugs Forecast by Applications (2019-2027)

Please Note: Data related to the Companies are subject to Availability.


Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources

  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources

  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)

  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*